ImmunityBio (NASDAQ:IBRX) Director Barry Simon Sells 151,967 Shares

ImmunityBio, Inc. (NASDAQ:IBRX) Director Barry Simon sold 151,967 shares of the stock in a transaction dated Tuesday, January 20th. The stock was sold at an average price of $7.20, for a total transaction of $1,094,162.40. Following the transaction, the director directly owned 3,091,604 shares in the company, valued at $22,259,548.80. The trade was a 4.69% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link.

ImmunityBio Trading Up 6.8%

ImmunityBio stock traded up $0.44 during midday trading on Wednesday, hitting $6.92. The stock had a trading volume of 95,661,091 shares, compared to its average volume of 33,482,678. The business has a fifty day moving average price of $2.54 and a 200 day moving average price of $2.52. ImmunityBio, Inc. has a 12 month low of $1.83 and a 12 month high of $7.98. The stock has a market cap of $6.82 billion, a P/E ratio of -16.88 and a beta of 0.03.

ImmunityBio (NASDAQ:IBRX) last released its earnings results on Wednesday, November 5th. The company reported ($0.07) EPS for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.03. The firm had revenue of $32.06 million for the quarter, compared to the consensus estimate of $31.88 million. On average, equities analysts anticipate that ImmunityBio, Inc. will post -0.92 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on IBRX shares. Jefferies Financial Group increased their target price on shares of ImmunityBio from $8.00 to $9.00 and gave the stock a “buy” rating in a report on Friday, December 12th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of ImmunityBio in a research report on Monday, December 29th. Piper Sandler increased their price objective on shares of ImmunityBio from $5.00 to $7.00 and gave the stock an “overweight” rating in a research note on Tuesday. Finally, D. Boral Capital reissued a “buy” rating and issued a $24.00 target price on shares of ImmunityBio in a report on Tuesday. Four research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, ImmunityBio has an average rating of “Moderate Buy” and an average target price of $12.00.

Hedge Funds Weigh In On ImmunityBio

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Slow Capital Inc. acquired a new stake in ImmunityBio in the 3rd quarter valued at approximately $25,000. Truist Financial Corp bought a new position in shares of ImmunityBio in the third quarter worth $27,000. Swiss Life Asset Management Ltd bought a new position in shares of ImmunityBio in the third quarter worth $27,000. Diversify Advisory Services LLC acquired a new position in shares of ImmunityBio during the second quarter valued at $27,000. Finally, Summit X LLC bought a new stake in shares of ImmunityBio during the second quarter valued at about $28,000. 8.58% of the stock is owned by institutional investors.

More ImmunityBio News

Here are the key news stories impacting ImmunityBio this week:

• Positive Sentiment: FDA discussions gave ImmunityBio a clear path to resubmit an sBLA for ANKTIVA in papillary non‑muscle invasive bladder cancer, and the company plans to submit additional information within 30 days — a direct catalyst for upside. ImmunityBio Stock Soars on FDA Talks for Anktiva sBLA Resubmission
• Positive Sentiment: Company press release confirmed a Type B End‑of‑Phase meeting with the FDA and outlined next steps for ANKTIVA’s sBLA, reinforcing the regulatory-path narrative that investors are rewarding. ImmunityBio Advances Regulatory Discussions with FDA
• Positive Sentiment: HC Wainwright raised its long‑term outlook (FY2030 EPS estimate to $0.68), signaling growing analyst optimism about ImmunityBio’s future earnings power (consensus had been negative).
• Positive Sentiment: At least one independent shop reaffirmed a “buy” and a high price target ($24), which may support further speculative buying interest. Benzinga
• Neutral Sentiment: The stock’s rally has extended over multiple sessions (reported as a 12‑day run in some outlets), driven in part by momentum trading and heavy volume rather than fresh clinical data. ImmunityBio (IBRX) rockets on 12th day, hits fresh high
• Neutral Sentiment: Market coverage notes short‑sellers are under pressure as the rapid share surge forces potential covering — a technical factor that can amplify volatility but isn’t a fundamental guarantee of sustained gains. Stock Market Today, Jan. 21: ImmunityBio Rises Again As Short-Sellers Face Losses
• Neutral Sentiment: Multiple outlets covered the FDA meeting and ensuing price moves; much of the market reaction reflects expectations about the timing and sufficiency of the planned resubmission analyses. ImmunityBio stock soars after FDA meeting on bladder cancer treatment
• Negative Sentiment: Some analysts and commentary warn of momentum risks — advising traders to be cautious or to trim exposure amid a speculative rally and the possibility that regulatory requests could require more data or time than investors expect. Top 3 Health Care Stocks You May Want To Dump In January

ImmunityBio Company Profile

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.